CPX-351 (Vyxeos™) for Transplant Eligible, Higher Risk Patients With Myelodysplastic Syndrome
Status:
Active, not recruiting
Trial end date:
2026-12-31
Target enrollment:
Participant gender:
Summary
This is a pilot and feasibility study of transplant eligible, higher risk myelodysplastic
syndrome (MDS) patients to determine the safety and tolerability of a lower -dose and
higher-dose CPX-351 regimen, with secondary objectives including complete remission (CR)
rates and proportion of patients proceeding to transplant.